

A Phenome-wide Association study of polygenic scores for Attention Deficit Hyperactivity Disorder in the electronic health record data

Maria Nearchou¹, Julia Sealock¹, Peter Straub¹, Sandra Sanchez Roige^{1,2}, James S. Sutcliffe¹, Lea Davis^{1,3,4,5,6}

¹Vanderbilt Genetics Institute, Vanderbilt University Medical Center, TN, USA, ²University of California San Diego Department of Psychology, Vanderbilt University, TN, USA, ³Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, TN, USA, ⁴Department of Biomedical Informatics, Vanderbilt University Medical Center, TN, USA, ⁵Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, TN, USA, ⁶Department of Molecular Physiology and Biophysics, Vanderbilt University, TN, USA

Correspondence: maria.nearchou@vumc.org, lea.k.davis@vumc.org

Attention Deficit Hyperactivity Disorder (ADHD)



- Attention Deficit Hyperactivity Disorder (ADHD) is a highly heritable childhood-onset neurodevelopmental disorder, which affects approximately 3-4% of children worldwide.
- Individuals with ADHD have a higher polygenic risk for ADHD (ADHD-PRS) compared to controls.
- High genetic risk for ADHD is also associated with higher BMI, neuroticism, anxiety, depression, alcohol use, smoking, anxiety depression, and lower general cognitive ability (Du Rosa, Coleman et al. 2018).
- Although PRS can be eventually implemented in clinical settings to improve diagnosis and risk stratification (Heldrop and Vray 2018), the majority of studies focus on highly ascertained research populations.
- Data from large Biobanks can overcome these limitations.
- In a sample of 10182 European ancestry individuals in the Penn Medicine Biobank, the ADHD PRS was not associated with ADHD. There were, however, significant associations with high risk for Tobacco Use Disorder (TUD), chronic airway obstruction, and type 1 diabetes, but also with low risk for psoriasis, benign neoplasm of skin, and screening for malignant neoplasm of the skin.

Study questions

1. Is ADHD-PRS associated with ADHD in BioVU?
2. What are the medical problems associated with ADHD-PRS?
3. Do these associations remain after adjusting for ADHD diagnosis and socioeconomic factors (measured by the Area Deprivation Index)?
4. What medical problems are associated with ADHD-PRS in different age categories?

Methods

PRS
We generated PRS for each individual in BioVU using the latest ADHD GWAS study from the Psychiatric Genomics Consortium (Demontis, Walters et al. 2017) as the discovery sample. Our BioVU sample included 66,378 unrelated individuals (84% males, median age of record (SD) = 48.2 (22.3)) of European ancestry.

Phenome Wide Association Study (PheWAS)
We standardized the ADHD PRS to have a mean of 0 and a standard deviation of 1 and used it as the predictor variable in the PheWAS. We required phenocodes to have at least 50 cases and included covariates for sex, median age across the EHR, current age, and the first ten principal components of ancestry. Results were considered statistically significant if they passed Bonferroni correction ($p < 3.3 \times 10^{-6}$).

PheWAS results

The ADHD-PRS was significantly associated with higher risk for ADHD (Odds Ratio (OR)=1.22, $p=3.22 \times 10^{-6}$). 92 phenocodes were significantly associated with ADHD-PRS ($p < 3.3 \times 10^{-6}$).

Figure 1. PheWAS plot of ADHD-PRS risk in the Penn Medicine Biobank. Phenocodes are sorted by the $-\log_{10}(P\text{-value})$ on the y-axis and by magnitude of the specific phenocodes on the x-axis. If the direction of the effect is positive, the color represents the direction of the effect (negative, the opposite direction).






Figure 2. PheWAS plot adjusted for tobacco use disorder (TUD) only (half of the associations remained significant, $P < 3.3 \times 10^{-6}$).

Figure 3. Phenocodes were associated with genetic liability to ADHD if unadjusted and if adjusted for 5 known US disorders.




Age-stratified



Follow-up analyses

We aimed to further explore the associations with pregnancy complications for the ages 12-18, and 19-25, and adjusted our analysis of variables like pubertal age for the females age 12-18 and also measured the phenocodes category 'early 50s or earlier' and 'younger' as potential confounders, as one variable. The association of the ADHD PRS remained when we adjusted for tobacco use.

Figure 4. Odds ratios of these associations by ADHD-PRS in the age groups (compared to females 20-25).



Overall, there was no evidence that ADHD diagnosis was associated with pregnancy complications (OR=1.02, $p=0.88$).

Discussion

Genetic liability to ADHD was associated with many medical diagnoses in the Vanderbilt bio bank, including ADHD itself

Replicated previous associations in research ascertained samples, including associations with smoking, higher BMI, Type 2 diabetes and major depressive disorder, while we also identified novel associations, including associations with pneumonia, sepsis, HIV, and PTSD.

Most findings remained significant when we adjusted for the diagnosis of ADHD indicating that genetic liability to ADHD is associated with varying health outcomes, over and above the clinical diagnosis.

After adjusting for TUD, only half of the associations remained significant, possibly due to direct or indirect associations with TUD.

Our study is the first to examine the associations of ADHD genetic risk with health outcomes over the lifespan in a clinical setting.

We found that the number of associations with adverse health outcomes increased with age, indicating that the effects of genetic liability to ADHD may have long term effects on health. However, it is also likely that these findings are a result of horizontal pleiotropy (i.e., shared genetic variants across disorders), or due to better power, taking into account that BioVU has older individuals compared to the general population.

Genetic liability to ADHD was associated with pregnancy complications, over and above ADHD and TUD diagnosis. Whether these associations are a result of pleiotropy remains to be examined.

Our findings further reinforce the utility of applying disorder-specific PRSs to biobank data to probe relationships amongst clinically-related conditions.

Acknowledgements

The project described was supported by the National Center for Research Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.